🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
97.81
+1.01 (1.04%)
At close: Nov 18, 2026, 4:00 PM EST
98.00
+0.19 (0.19%)
After-hours: Nov 18, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Zenkuda’s DAYBREAK results supported six-month dosing for many patients, and its three-indication BLA was targeted for year-end 2026. KSI-101’s PEAK 1 readout was expected before Christmas, while KSI-501’s DME Phase III program was accelerating.

Maury Raycroft
Biotech Analyst, Jefferies

Hi, everyone. My name is Maury Raycroft, and I am one of the Biotech Analysts at Jefferies. It is with great pleasure that I would like to welcome Victor Perlroth, the CEO of Kodiak Sciences. Thanks so much for joining us today, Victor.

Victor Perlroth
CEO, Kodiak Sciences

Thanks, Maury. Glad to be here. Thanks.

Maury Raycroft
Biotech Analyst, Jefferies

We are going to do fireside chat format. Maybe for those who are new to the story, if you can give a brief intro to Kodiak.

Victor Perlroth
CEO, Kodiak Sciences

S ure. It is hard to put it all in a couple of words, but we call ourselves a pre-commercial retina-focused biotech company. We are developing medicines for the big diseases, by and large, in retina. We have had an exciting year so far. We had top-line data in March from the GLOW2 study, which is our drug, tarcocimab, or Zenkuda, in diabetic retinopathy. It was the second phase III, and it used our commercial or new formulation process, and it was a very strong, very exciting, very safe-looking medicine coming out of that second diabetic retinopathy study. Then we had that same drug in the DAYBREAK study. That had the readout in late September, actually alongside maybe its little brother, the KSI-501 bispecific conjugated medicine, both ABCs, we call them, antibody biopolymer conjugates, in treatment-naive wet AMD. That was also a very successful study. We were extremely pleased.

Zenkuda, in particular, looked very strong against EYLEA in that treatment-naive wet AMD population. Our objectives going into the study were to look for very strong immediacy of effect, as well as looking for long-interval durability. We were very pleased to see very powerful immediacy, tracking, if anything, better than EYLEA. Then we took the majority of the patients to six months dosing, with a very strong vision gain and efficacy through that kind of durability interval phase and through the endpoint. We used, I would say, a very honest study design in DAYBREAK, where the Zenkuda-treated patients. We used a sort of a very, very sensitive kind of algorithm. If any fluid fundamentally was present at the limit of sensitivity of these OCT machines, then the patient would be treated.

That meant that those durability kind of numbers of the majority being treated on six months really are what we call kind of real world. The physicians and the community can then expect to be able to see a very powerful immediacy in their patients, in the clinic, and also a fundamentally, I think, game-changing and disruptive level of durability. I think the readout really changes the game for all drug developers in retina, and forces everybody to think a little bit differently, because we have a biologic that fundamentally can deliver what everybody has sort of been trying to do, which is high efficacy/immediacy, which is what the current medicines, EYLEA HD, VABYSMO, deliver, what they give, and a really differentiated kind of durability.

I think, in advance of the DAYBREAK. Well, in advance of the GLOW2 study, I think, what we messaged is, I think, we thought maybe investor community was underappreciating the potential of the GLOW2 readout, because it was going to read through on the new formulation, and GLOW2 was sort of a repeat of the GLOW1 study. We did very well and showed a lot of strength in the GLOW2 readout. Then I think in advance of DAYBREAK, we were more measured. We didn't know. EYLEA is a very strong comparator in a mass study. What we did say is that our durability generally had over-delivered. Where we were weak was on that immediacy and some 10%, 20% of the patients. We just didn't know how good we were going to be.

We thought going into the readout that we would be pretty good on the immediacy. We didn't know whether that meant slightly weaker than EYLEA, the same, or slightly better. We didn't know on the durability, because we had really used these unknown, very sensitive criteria. But we really blew through that, and that was very exciting and I guess a surprise. I think we also did well with the KSI-501 bispecific conjugate in wet AMD. Met the endpoint, and that sets the stage for that molecule to move in to the ALTO phase III study, which is enrolling in DME, and that's accelerating. But I think, having said that, historically, now we're in the face of the KSI-101 phase III readout, which is really a new indication area. It's going up against sham.

It's in a disease that we call MESI, which is inflammatory macular edema, or Macular Edema Secondary to Inflammation. Macular edema is what retina doctors treat today. It's just they're treating it for wet AMD, they're treating it for DME, they're treating it for RVO. We have a new agent, a very powerful, very strong agent going up against sham in the PEAK and PINNACLE pivotal program, and we're looking at the readout for PEAK 1 before Christmas. We're on track for that, obviously fully enrolled for PEAK 1. It's really a three-study pivotal program, and the first one is this first readout. As I've said publicly, I mean, I'm very excited and we're very excited for the readout.

This is a very powerful medicine in a very sick patient population, going up against sham, and we're hoping for a very powerful readout that could be really important for this very sick population, where there really is no therapy whatsoever. That's very good. Just to close out on an intro, we also set up a shelf and an ATM coming out of DAYBREAK. We did raise a little bit on the ATM over the past couple weeks, about $70 million, which is a nice bridge through the PEAK 1. From there, we would have an expectation to further capitalize the company. We're on track for the BLA for Zenkuda, tarcocimab, before the end of this year, in three indications of wet AMD, retinal vein occlusion and diabetic retinopathy. So that's very exciting.

It's obviously a complicated multi-indication BLA with an antibody conjugate, so the teams are very busy on that. We're quite busy on the PEAK 1, top-line data and the continuation of that program with PINNACLE and PEAK 2 and PINNACLE. We'd be focused on the BLA for that asset. Whether we can file on a single study, could potentially file in April. Alternatively, if we're going to wait for the PEAK 2 and PINNACLE's fully enrolled. PEAK 2 just has a few more patients to go, to be honest, with the 24-week endpoint. So we'd be looking at maybe May, June for top-line data for PEAK 2 and PINNACLE, and we could file with 48-week safety data on PEAK 1 together with primary endpoint data for PEAK 2 and PINNACLE, like mid-next year. So it's pretty exciting. The KSI-501, as I said, is in the ALTO-DME study, and that's accelerating.

We're quite excited about the potential for that bispecific conjugate with the free protein and the conjugate to really do something special in DME. In summary, we're a pretty interesting retina company, with three late-phase assets, BLAs targeted for this year, next year, and maybe 2028 for the third asset. Hopefully, we could be approved with Zenkuda by the end of 2027 and maybe be approved by KSI-101, let's say, in early 2028. Those are major diseases. We have a lot of science underlining, underpinning what we do. We've learned a lot over the years, and we're trying to be more conservative in our phase III study designs. We've really turned some pretty differentiated data cards for Zenkuda, certainly in the big anti-VEGF market. I think KSI-101 can look really differentiated in this MESI market, which I do think is underappreciated in terms of its size.

I'll stop there.

Maury Raycroft
Biotech Analyst, Jefferies

That was a great intro. I think you covered everything.

Victor Perlroth
CEO, Kodiak Sciences

Okay, let's go.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. We'll go back to the first trial, the DAYBREAK study. I think that for hearing your intro there's a lot happening, especially over the next couple quarters here. So, definitely important time for the company. You had the DAYBREAK readout, which I think was better than what you were expecting, better than what we were expecting as well. Maybe digging into the data, you had 54% of the Zenkuda patients that reached six months, while about 17% remained at monthly or every other month. Is there a perspective you can provide into baseline or early treatment characteristics that differentiated those two groups, and how early could physicians identify patients unlikely to extend?

Victor Perlroth
CEO, Kodiak Sciences

Mm-hmm. Well, it is challenging to know a priori for any patient, in particular, I guess I would say the treatment-naive population, which is the population that we largely enroll. Nobody has any good view today of really understanding which patient is going to be a long-interval patient and which patient is going to be short interval. I think we did separately, the science of our ABCs is to make antibody conjugates. So you make the antibody larger by virtue of the zwitterionic, like this polymer conjugation that we make. But at the same time, we have that free protein to bring the immediacy. I think we did pretty interesting science where we dosed patients with the conjugated form and then did these aqueous taps where you sample the eye over time. And we shared the data from all the individual patients.

What you see is that every patient had a very big bend kind of exit rate in that patient, but actually, there is tremendous variability in the exit characteristics on the eyeball between patients. And that half-life ranged from 10 days out to 50 days. And like I said, and you mentioned, we did bring more than half the patients to the six-month interval in the DAYBREAK study. And we used the most sensitive criteria available, limit of sensitivity of fluid detection of the machine with regards to intraretinal fluid and subretinal fluid. And actually, I think that the durability data are even stronger than that because we capped the patients at six months. So many of the patients would have gone further, except we forced them to be dosed at six months. So there is tremendous inter-patient variability. We see that supported by the science.

The goal is to do better in every patient than what they can currently do with today's existing agents. So, like some patients may be on a Q3 week interval. Well, maybe we do Q4. Other patients are maybe on Q4 today, and we take them to Q6. Other patients on Q8, maybe we take them to Q12, and maybe we take the Q12 to Q16, Q20, or Q24. So the goal is to bring the combination of that immediacy and the durability to change the game for every patient. But we do not need to know a priori whether a patient is going to be a six-month or a one-month. That is really empiric.

The goal is to say, well, we hope through the combination of the free protein and the conjugated protein, the immediacy and the durability, that whatever they are able to achieve today, they are going to be on something—

Maury Raycroft
Biotech Analyst, Jefferies

Better.

Victor Perlroth
CEO, Kodiak Sciences

—a little better with our ABCs.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Yeah, that's interesting. Because the six months was the protocol maximum, how many patients reached six months without meeting retreatment criteria and may have been capable of extending further? Maybe talk about the implications of that.

Victor Perlroth
CEO, Kodiak Sciences

Yeah, we haven't disclosed that number. There's a lot there in the DAYBREAK study, and obviously, we'd like to publish that and thinking about what would be the right publication, the right journal, that would be interested to accept that. I think it's a lot more. I was pretty surprised. It's certainly more than a majority of the patients did not meet criteria, which meant that they would, in theory, be able to go longer, and they were not wet. Yeah.

Maury Raycroft
Biotech Analyst, Jefferies

Got it.

Victor Perlroth
CEO, Kodiak Sciences

I am glad we had the cap, actually. I think six months is a good interval. I think in the real world, it may turn out that patients aren't scheduled every six months, but in many cases, maybe they're scheduled every four. Then, if they go on vacation or if they can't get driven to the clinic, then there's not a lot of anxiety if they come in a couple weeks later, for example.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Maury Raycroft
Biotech Analyst, Jefferies

Makes sense. Among patients who reached six months after loading, how many subsequently required interval shortening? What should investors focus on in the year two data to assess whether six-month durability is sustained?

Victor Perlroth
CEO, Kodiak Sciences

Mm-hmm. Well, it's not predictable exactly. I think what's more important than getting into the details of the intermediate kind of aspect of the study is it more impressive that 48% of the patients were on six months coming out of the loading phase? Because often we see durability intervals getting longer as you go further out. Or is it more impressive that a majority of the patients through the endpoint were at six months or, let's say, longer? I mean, they're both very powerful numbers. Some physicians think the 48% coming out of the loading phase is more impressive than the majority going through the endpoint at six months. I think it's sort of like fielder's choice. They're both very powerful, and you have to combine that, right, with this idea that it's really a real-world durability.

The physicians, their job is to do their job, and I think because there's such inter-patient variability that we talked about, right, I do not think you just forget about the patient. But the fact that we do so well coming out of the loading phase is very impressive.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Got it. And it was one of the questions that came up is just with the loading doses in year one, I guess, how does that contribute to durability? And with fewer treatments in year two, should we expect some patients to lose the six-month interval and require more frequent dosing?

Victor Perlroth
CEO, Kodiak Sciences

I think it's likely to be a mixture of both. You may lose that a little bit for some patients, but you're also going to gain it for others. Because like I said, as you look to the longer studies, some of the sponsors suggest that their long-interval durability numbers are increasing. It's a little bit complicated because a lot of durability is a completer analysis, and as you go to year two or beyond, there's a bit maybe of a selection bias. That's why coming out of the loading phase and going through year one's important. I think a majority or more than a majority is a big number, so I think we're in a very good position. And like I said, you may see a little bit of deterioration on some patients, but you're going to gain it back on other patients.

I think the core science of our— What's sort of nice is we have a real core science of our durability, and also with the free protein and the conjugated. And we didn't post middle-of-the-road data, right? We posted really strong immediacy and strong fluid control through the whole study, and we posted very strong vision through the loading phase and strong vision through the endpoint.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Makes sense. And maybe for the BLA, if you can talk about just gating factors there before you can get the BLA submitted. Are there any unresolved questions from FDA? You've got five studies that are going into this, and so maybe it's more complicated than other BLAs.

Victor Perlroth
CEO, Kodiak Sciences

Mm-hmm. Well, there's a lot of pretty good tools now, I would say, for putting the BLAs together. It is a very complicated BLA, I would say. We have the antibody and we have the polymer, and then we have the conjugate, and it's for retina. We have the pre and post-change formulations, but fundamentally, everybody has changes to their formulations as they move into commercial scale. We have the three different diseases, and we have two studies in the diabetic retinopathy and two studies in the wet AMD, plus we have the retinal vein occlusion. It has a lot of pieces and integrating all those, and then of course, we have all the studies on all the pieces. I'm proud of the team. All the pieces are coming together. I believe we're on track to file this year.

There's no fundamental unknowns at this point, so it's just a matter of assembly and filing. From an FDA standpoint, I think the most important is we do have agreement to file the three indications in a single filing. We also have an agreement, really from before we made the change in the formulation as we shifted into the commercial facility, and before we ran the GLOW2 and DAYBREAK studies. We have agreement in writing from them that if we ran one more phase III study with the new kind of post-change formulation, that we would bridge all the prior studies. Then, of course, we ran not just one, we ran the GLOW2 and the DAYBREAK studies. So, I think we're in very good shape there, and I think we're excited to engage with the FDA on the submission and kind of move into the post-submission phase.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah.

Victor Perlroth
CEO, Kodiak Sciences

Yeah.

Maury Raycroft
Biotech Analyst, Jefferies

Okay. So it sounds like you're not anticipating too many surprises from the BLA filing at this point.

Victor Perlroth
CEO, Kodiak Sciences

No.

Maury Raycroft
Biotech Analyst, Jefferies

Maybe looking ahead to what a label could look like, what dosing language do you believe could support dosing in wet AMD and DR? I guess, would you seek up to every six months, or would the label more likely describe the full monthly to six-month individual range?

Victor Perlroth
CEO, Kodiak Sciences

Well, I do not think that's necessarily known or preordained. We hope that the label would be pretty straightforward and pretty simple. We believe that the label should reflect the drug the physicians are going to be dosing, so we think a focus on the post-change and the commercial formulation would make a lot of sense. In terms of the dose interval, I think the EYLEA HD label, as opposed to the VABYSMO label, the VABYSMO label is pretty complicated and it's got a lot in there, and they basically got what they tested, whereas the EYLEA HD label is pretty straightforward and pretty simple. I hope that as we engage with FDA, they'll focus on a fairly simple label, which is easier for physicians to understand.

Certainly in the DAYBREAK study, I think, like I said, we ran a very honest study with real-world criteria, and I think physicians should have the ability to dose Q4 all the way through Q24. In RVO, we also had the first six months and then we had the second six months, and they kind of had different parameters. I hope we'd be able to, certainly in the first six months, we did two loading doses and then we did every eight weeks up through week 24. Certainly some patients would have benefited probably from monthly, and we certainly have monthly safety from the DAYLIGHT monthly wet AMD study. Then in the second six months, the RVO patients floated out to Q24 weeks. So I hope we would end up with a pretty broad and flexible label in RVO.

In DR, as you know, the GLOW2 study had three loading doses once a month, and then went out to quarterly and then to every six months. Then in the GLOW1, we just had a dose at day zero, then we went out eight weeks, and then we went out 12 weeks, and then we went out 24 weeks. So, I think the ability to either have what I call a very gentle on-ramp, where you go eight weeks and then 12, and then 24, or the ability to do three loading doses once a month, because we also added more severe patients, like moderate DME patients, we added in GLOW2, and we added patients that had kind of early proliferative disease. They all did extremely well. So I think where we end up, obviously it would be nice to have a one-month through six-month label in DR.

We certainly have those three loading doses there. We certainly have safety on monthly from the DAYLIGHT study, all the way out to a year. So I think that will be part of the very interesting dialogue. I mean, my view is that physicians should be educated in the label, and then they should do their job of trying to decide what the best regimen is going to be. I think we have very good benefit-risk for patients across the diseases, especially with the post-change formulation. So why do not we kind of see what we get? I think from a safety perspective, it doesn't matter whether it's all pooled or whether it's individual study, or whether it's focused more on the post-change formulation, because I think our safety across all three of those kind of different analyses looks very safe.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Okay. For initial adopters, maybe talk about the patient population that you think doctors are going to give Zenkuda to first. Then also on pricing and how you factor in potentially fewer treatment injections.

Victor Perlroth
CEO, Kodiak Sciences

Hmm. Well, I think the framework that we like to think about is that kind of four-quadrant plot where you have efficacy, immediacy on that y-axis, and then durability on the x-axis. The concept is, well, we're really the lone agent up in that upper right quadrant, okay, with immediacy and durability. I think, to me, that means that physicians, and it's really a holy grail to try to have a biologic that can deliver immediacy and durability. So, I hope that Zenkuda could be a drug that could be a go-to agent for every patient. Like I said, if whatever frequency they're being dosed today, I hope it could be longer with strong immediacy in the clinic. That would be exciting. I do not know whether that means we can have 10% of the market or 20% or 30% or whatever it is.

I think it's a big market. I think as the branded agents come, we have the science to support the best branded agent. So I think that's really exciting. I do not know what the pricing should be. We obviously, people have a lot of arguments and disagreements about it, but one thing is, it's taken us almost 20 years to get here, and it'll take about $2 billion, let's say, to get two agents to approval. So, it does take time and money, and we require the support of the investor community to do that at risk. So, I do not know how that translates, but I think we'll try to get to the right number. Yeah.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Maybe briefly on KSI-501 and the ALTO study. So, for KSI-501 in wet AMD, there wasn't an obvious efficacy advantage over aflibercept in the broad DAYBREAK population. Have you identified any pre-specified or biologically plausible subgroups in which IL-6 inhibition added benefit?

When could you provide an update on that? Is there still a registrational path for KSI-501 in wet AMD?

Victor Perlroth
CEO, Kodiak Sciences

Yeah. I mean, as to registrational path, I think it will play out, let's say, over. I mean, certainly we would want the drug to be available in wet AMD. I think the treatment-naive population is maybe the worst population for that kind of bispecific agent, because I think it will work best in the most complicated pathology, which is a more commercial, clinical commercial pathology. That is where the IL-6 might deliver some added benefit. We have not spent enough time in the KSI-501 data because we have been very busy. Part of the KSI-501 now is really the acceleration with our DME program, where based on the Roche data where they showed anti-IL-6 dose together with Lucentis in DME suggests the possibility for real curve shift on vision.

If that is the case, we are going to run the ALTO phase III program to definitively, if our IL-6 VEGF conjugate with the free protein and the conjugated, with those two mechanisms, if there is the ability to show non-inferiority and to superiority, we are going to run the study to show that. We are accelerating that. We are enrolling a lot of patients, and I would say it is quite exciting opportunity for that molecule. Whether we could file on the single wet AMD study, I think really depends a lot on what we see with FDA over the next year in terms of whether they are kind of being more liberal or whether they are kind of keeping the same more historical approach. I think for Kodiak, we kind of can win either way.

If they are kind of allowing more single study filings, that allows us to have sort of a value acceleration across all of our three late-phase programs. Whereas if they keep more of a traditional dual study thing, I think we have been well capitalized and we run large phase III programs, and we know how to do that, and we can win there too, and it just keeps more people out with molecules that are somewhat less known.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. For the ALTO study, anything else you want to highlight just for the statistical design there? One of our questions was if KSI-501, if any of the KSI-501 arms are powered for superiority.

Victor Perlroth
CEO, Kodiak Sciences

Yeah. So the answer is that it's initially a non-inferiority analysis, and if we show that, then we look for superiority, and it is powered for a superiority if we can find it. If it's there, we're going to power. It is powered, and we'll continue to power it to be able to showcase that superiority.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. For the MESI readout coming up soon—

Victor Perlroth
CEO, Kodiak Sciences

Yes.

Maury Raycroft
Biotech Analyst, Jefferies

—there is the view that there could be a lot of heterogeneity in this patient population. Maybe just talk about how that factors into your assumptions there, and if there's any risk that FDA could maybe lead to a narrower label versus the broad MESI indication.

Victor Perlroth
CEO, Kodiak Sciences

Well, I think the label population should be the population that we studied, and I think we did a good job of communicating with FDA before we initiated the study to really reflect the breadth of the actual population. What it is called or whatever, I think is less important, but we have a very broad population that includes, I would say, extremely sick patients on one bookend, and then of course more typical UME or uveitic macular edema, and then also kind of these refractory post-surgicals. I think it is very broad. I think it is a broad population. It is an aggregated population. It is fundamentally autoimmune attack against the retina, and there are so many reasons and so many populations. What is amazing and what we saw in the APEX is, let us say practically every patient had a very strong and very immediate response to therapy.

We see KSI-101 as a very much a unifying therapy to bring all of those kinds of different conditions, and you no longer need to have some Sherlock Holmes to figure out, well, what the patient has that is causing this autoimmune attack. We are treating autoimmune attack locally, and it is very empowering, and we think a lot of retina patients actually have MESI, and that will be very exciting clinically and commercially.

Maury Raycroft
Biotech Analyst, Jefferies

Phase III readout for MESI, December.

Victor Perlroth
CEO, Kodiak Sciences

Yes.

Maury Raycroft
Biotech Analyst, Jefferies

We are excited to see the results there. Thanks so much for joining us today.

Victor Perlroth
CEO, Kodiak Sciences

Thanks a lot, Maury. Appreciate it.